Merck KGaA expands its deal with Pfizer/BioNTech with an eye on a key vaccine manufacturing bottleneck
As Pfizer and BioNTech’s vaccine delivery runs behind schedule in the EU, Merck KGaA is aiming to boost production by accelerating its supply of custom lipids to BioNTech.
The Darmstadt, Germany-based biotech has promised to expand its production of lipids, which are critical in getting the mRNA technology into the body. Complicating matters further is that only a select few manufacturers are currently equipped to manufacture the lipids in standards consistent enough for vaccine production.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.